黄连-吴茱萸药对治疗非酒精性脂肪性肝炎的机制:网络药理学与实验验证
该研究采用网络药理学结合小鼠体内实验,探讨黄连-吴茱萸药对(HWHP)治疗非酒精性脂肪性肝炎(NASH)的机制。网络药理学筛选出41个活性成分和198个靶点,其中51个与NASH相关,KEGG提示NOD样受体信号通路重要;体内实验显示HWHP通过抑制NLRP3炎症小体减轻肝脏炎症和脂肪变性。
要点
- HWHP可能通过抑制NLRP3炎症小体改善NASH。
- 网络药理学提示NOD样受体信号通路是关键通路。
- 体内实验验证HWHP降低血脂和肝酶,减轻炎症。
核心结论
- HWHP通过抑制NLRP3炎症小体减轻小鼠NASH的炎症和肝脏脂肪变性。
研究设计与样本
- 研究基于网络药理学预测,并采用小鼠模型进行体内实验验证。
- 活性成分和靶点来自TCMSP数据库,NASH相关基因来自DisGeNET数据库。
- 使用Cytoscape构建「药物-成分-靶点-疾病」网络,并进行GO和KEGG富集分析。
- 采用AutoDock软件进行分子对接,评估关键靶点与活性成分的结合亲和力。
主要发现
- 筛选出HWHP的41个活性成分和198个靶点,其中51个共同靶点与NASH相关。
- GO功能富集分析显示HWHP可能通过调节炎症反应影响NASH。
- KEGG通路富集提示NOD样受体信号通路在治疗NASH中可能起重要作用。
- 分子对接结果显示大多数HWHP成分能与NLRP3成功对接,结合能良好。
- 体内实验显示HWHP减轻肝脏炎症、改善肝脂肪变性,降低TC、TG、LDL-C、ALT和AST。
临床怎么用
- 提示HWHP可能作为NASH的潜在治疗选择,其机制与抑制NLRP3炎症小体相关。
- 网络药理学与实验验证结合的方法可用于阐释中药药对的作用机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: The Huanglian-Wuzhuyu herb pair (HWHP) is a classic Chinese herbal formula consisting of the root of Coptis chinensis Franch and dried, nearly mature scented fruit of Tetradium ruticarpum (A.Juss.) T.G.Hartley. It is widely utilized to treat gastrointestinal and liver diseases such as diarrhea, dysentery, cholestasis, hepatocellular carcinoma, and nonalcoholic steatohepatitis (NASH). However, the mechanism of HWHP in treating NASH remains poorly understood. AIM OF THE STUDY: This study investigated the mechanisms of HWHP in NASH treatment via network pharmacology and validated the results through in vivo experiment using mouse models. MATERIALS AND METHODS: The compounds and targets corresponding to the active ingredients of HWHP were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) database. The genes associated with NASH were obtained from the DisGeNET database. Cytoscape software was employed to construct a "drug-ingredient-target-disease" network. Furthermore, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were employed to analyze the related signaling pathways affected by HWHP. Moreover, AutoDock software was used to assess the potential binding affinity between the key targets of the hub pathway and the bioactive compounds. Subsequently, in vivo experiment was conducted to verify the findings of network pharmacology. RESULTS: A total of 41 active compounds and 198 targets of HWHP were screened, of which 51 common targets were related to NASH. GO functional enrichment analysis revealed that HWHP may affect NASH by modulating inflammatory response. KEGG pathway enrichment suggested that the NOD-like receptor (NLR) signaling pathway may play an important role in treating NASH. Molecular docking results demonstrated that most HWHP components were successfully docked to NLRP3 with good binding energy. In vivo experiments revealed that HWHP alleviated liver inflammation, improved liver steatosis, reduced TC, TG, LDL-C, ALT, and AST, decreased mRNA expressions of IL-6, IL-18, and TNF-α in the liver, and lowered the expressions of NLRP3, pro-IL-1β, and ASC protein. Also, immunohistochemical findings presented downregulation of caspase-1 and IL-1β by HWHP. CONCLUSIONS: The results disclosed that HWHP ameliorates NASH in mice by reducing inflammation and liver steatosis via inhibition of NLRP3 inflammasome. This study revealed the mechanism of HWHP in treating NASH through experiments.
引用
- Zhang X, Gao R, Zhou Z, et al. Uncovering the mechanism of Huanglian-Wuzhuyu herb pair in treating nonalcoholic steatohepatitis based on network pharmacology and experimental validation. J Ethnopharmacol. 2022. PMID: 35644437. doi:10.1016/j.jep.2022.115405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。